Linked Data API

Show Search Form

Search Results

1001918
registered interest false more like this
date remove filter
answering body
Department of Health and Social Care remove filter
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Rare Diseases: Drugs more like this
house id 1 remove filter
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, whether officials in his Department have had discussions with the Scottish Government on the (a) Patient and Clinician Engagement system, (b) its effect on approval rates for new rare disease medicines in Scotland and (c) potential lessons from that system for NHS England. more like this
tabling member constituency Bury North more like this
tabling member printed
James Frith more like this
uin 188233 remove filter
answer
answer
is ministerial correction false more like this
date of answer less than 2018-11-14more like thismore than 2018-11-14
answer text <p>Officials have had no such discussions. Health is a devolved matter and the availability of medicines for the treatment of rare diseases in Scotland is an issue for the Scottish Government.</p> more like this
answering member constituency Winchester more like this
answering member printed Steve Brine more like this
question first answered
less than 2018-11-14T11:21:33.263Zmore like thismore than 2018-11-14T11:21:33.263Z
answering member
4067
label Biography information for Steve Brine more like this
tabling member
4637
label Biography information for James Frith more like this